LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years

Expert Opin Drug Deliv. 2017 Sep;14(9):1131-1140. doi: 10.1080/17425247.2017.1353972. Epub 2017 Aug 2.

Abstract

Globally, intrauterine devices (IUDs) are the second most commonly used form of reversible contraception because of their high efficacy, safety, convenience and cost effectiveness. The levonorgestrel releasing intrauterine system with daily average release of 20 mcg (LNG-IUS 20) is the popular choice because of its favorable bleeding patterns and many noncontraceptive benefits. A three year (LNG-IUS 8) became available three years ago. More recently, the LNG-IUS 12 was added. This new IUD shares a smaller frame, narrow inserter and lower rate of amenorrhea with the LNG-IUS 8, but it offers the five years of contraceptive protection of the LNG-IUS 20. Areas covered: This article provides information on the contraceptive efficacy, safety and tolerability of this new IUS based on approximately 60,000 cycles of use. Where available, the impacts of subject age, parity and body mass index (BMI) on study outcomes are reported. Expert opinion: This new LNG-IUS 12 with mid-dose hormone levels, smaller frame and longer effective life fills a niche that may better meet the needs of women who might appreciate the narrow insertion tube and/or the lower rates of amenorrhea. Cost will ultimately help determine success.

Keywords: Contraception; Kyleena; LNG-IUS 12; contraceptive efficacy; intrauterine contraception; levonorgestrel; long acting contraception; progestogen contraception.

MeSH terms

  • Contraception
  • Contraceptive Agents, Female / administration & dosage*
  • Contraceptive Agents, Female / adverse effects
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Intrauterine Devices, Medicated*
  • Levonorgestrel / administration & dosage*
  • Levonorgestrel / adverse effects
  • Pregnancy

Substances

  • Contraceptive Agents, Female
  • Levonorgestrel